Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 1.3% – Here’s Why

Hemogenyx Pharmaceuticals Plc (LON:HEMO) shares dropped 1.3% during trading on Tuesday . The stock traded as low as GBX 1 ($0.01) and last traded at GBX 1.10 ($0.01). Approximately 4,262,927 shares changed hands during mid-day trading, a decline of 57% from the average daily volume of 9,958,841 shares. The stock had previously closed at GBX 1.11 ($0.01).

Hemogenyx Pharmaceuticals Price Performance

The business has a 50-day moving average of GBX 1.25 and a 200 day moving average of GBX 1.33. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09. The firm has a market capitalization of £13.51 million, a P/E ratio of -95.00 and a beta of 3.14.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.